Aprogen Turns To IPO To Support Biosimilar Pipeline Expansion
This article was originally published in PharmAsia News
Executive Summary
South Korea's Aprogen, which has reached global partnership with Japan's Nichi-Iko for development of its biosimilar versions of Remicade, Herceptin and Rituxan/Mab Thera, is seeking to independently conduct clinical development of other biosimilar products by using the proceeds from its domestic initial public offering.
You may also be interested in...
World-First Nod For Yuhan's Lung Cancer Drug, In Korea
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Need a specific report? 1000+ reports available
Buy Reports